These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 19450103)

  • 1. Clinical trials and health economics--a marriage of convenience or a marriage made in heaven?
    Bakhai A; Greenberg D
    J Med Econ; 2008; 11(3):541-6. PubMed ID: 19450103
    [No Abstract]   [Full Text] [Related]  

  • 2. Design and analysis issues for economic analysis alongside clinical trials.
    Marshall DA; Hux M
    Med Care; 2009 Jul; 47(7 Suppl 1):S14-20. PubMed ID: 19536012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health economics in technology development: is it worth it?
    Lee D
    J Nucl Med; 2008 Jun; 49(6):48N-50N. PubMed ID: 18511826
    [No Abstract]   [Full Text] [Related]  

  • 4. How to read clinical journals: VII. To understand an economic evaluation (part B).
    Can Med Assoc J; 1984 Jun; 130(12):1542-9. PubMed ID: 6428730
    [No Abstract]   [Full Text] [Related]  

  • 5. [Follow up studies as a condition for drug subsidizing].
    Kieler H; Ekbom A; Fored M; Montgomery SM; Wettermark B
    Lakartidningen; 2009 May 13-19; 106(20):1406-7. PubMed ID: 19585842
    [No Abstract]   [Full Text] [Related]  

  • 6. [German recommendations for health economic evaluation. Revised edition of the Hannoverian consensus. Hannoverian Consensus Group].
    Dtsch Med Wochenschr; 1999 Dec; 124(49):1503-6. PubMed ID: 10629671
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of different study designs: an overlooked parameter in clinical research.
    Falagas ME; Bliziotis IA
    J Clin Epidemiol; 2007 Mar; 60(3):215-6. PubMed ID: 17292014
    [No Abstract]   [Full Text] [Related]  

  • 8. Future costs in economic evaluation. A comment on Lee.
    Feenstra TL; van Baal PH; Gandjour A; Brouwer WB
    J Health Econ; 2008 Dec; 27(6):1645-9; discussion 1650-1. PubMed ID: 18823670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The cost of innovative drugs].
    Reggio S
    Recenti Prog Med; 1999; 90(7-8):371-2. PubMed ID: 10429514
    [No Abstract]   [Full Text] [Related]  

  • 10. Grading systems for cost-effectiveness studies: is the whole greater than the sum of the parts?
    Stearns SC; Drummond M
    Med Care; 2003 Jan; 41(1):1-3. PubMed ID: 12544536
    [No Abstract]   [Full Text] [Related]  

  • 11. Randomized concentration-controlled trials: motivations, use, and limitations.
    Kraiczi H; Jang T; Ludden T; Peck CC
    Clin Pharmacol Ther; 2003 Sep; 74(3):203-14. PubMed ID: 12966364
    [No Abstract]   [Full Text] [Related]  

  • 12. [Introduction to pharmaco-economics: 'glossary'].
    Auray JP
    Therapie; 2001; 56(2):89-91. PubMed ID: 11471379
    [No Abstract]   [Full Text] [Related]  

  • 13. Design of the "Thorough QT Study".
    Darpo B; Sager P
    Clin Pharmacol Ther; 2008 Apr; 83(4):529; author reply 530. PubMed ID: 18043696
    [No Abstract]   [Full Text] [Related]  

  • 14. Economic analysis and complex randomized controlled trials.
    Delaney B
    Fam Pract; 2007 Sep; 24(4):293-4. PubMed ID: 17728291
    [No Abstract]   [Full Text] [Related]  

  • 15. [Economic analysis of therapeutic actions--fundamental concepts and examples of application].
    Shinbo T
    Nihon Naika Gakkai Zasshi; 2000 Jun; 89(6):1206-11. PubMed ID: 10892199
    [No Abstract]   [Full Text] [Related]  

  • 16. Adapting pharmacoeconomic data and methods to extend the postpublication utility of analyses.
    Lyles A
    Clin Ther; 2009 Jan; 31(1):192-3. PubMed ID: 19243717
    [No Abstract]   [Full Text] [Related]  

  • 17. Economic evaluation of pharmaceuticals: what are reasonable standards for clinical evidence--the Australian experience.
    Hill S; Henry D; Pekarsky B; Mitchell A
    Br J Clin Pharmacol; 1997 Nov; 44(5):421-5. PubMed ID: 9384457
    [No Abstract]   [Full Text] [Related]  

  • 18. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of economic models in randomized clinical trials.
    Hlatky MA
    Am Heart J; 1999 May; 137(5):S41-6. PubMed ID: 10220595
    [No Abstract]   [Full Text] [Related]  

  • 19. [Non-interventional studies give good follow-up possibilities. Increased demand both nationally and internationally can be predicted].
    Strandberg K
    Lakartidningen; 2007 Sep 12-18; 104(37):2597-9. PubMed ID: 17970395
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness of endoscopic screening followed by surveillance for Barrett's esophagus: a review.
    Barbiere JM; Lyratzopoulos G
    Gastroenterology; 2009 Dec; 137(6):1869-76. PubMed ID: 19840798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.